Kalobios Pharmaceuticals Inc (KBIO) 0.45 $KBIO
KaloBios Announces Upcoming Investor Conference Participation
PR Newswire - Tue Feb 03, 3:01PM CST
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that it will present at the BIO CEO & Investor Conference, and will participate in an analyst-led fireside chat at the Leerink Partners 2015 Global Healthcare Conference next week in New York City, New York.
KBIO: 0.45 (+0.06)
Biotech Weekly: When To Dash For The Trash (And When Not To)
Daniel Ward - at Seeking Alpha - Mon Feb 02, 8:40AM CST
KBIO: 0.45 (+0.06), CYCC: 0.62 (-0.01), TRGT: 2.50 (-0.01), SPHS: 0.44 (-0.01), ABIO: 0.70 (+0.03), APPY: 0.45 (-0.01), OCLS: 0.80 (-0.01)
KaloBios discloses departure of CEO & president David W. Pritchard
M2 - Fri Jan 09, 7:45AM CST
Monoclonal antibodies company KaloBios Pharmaceuticals (NasdaqGM:KBIO) announced on Thursday the retirement of David W. Pritchard as its president and chief executive officer with immediate effect.
KBIO: 0.45 (+0.06)
KaloBios CEO Pritchard resigns; shares -7.4% AH
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 5:45PM CST
KBIO: 0.45 (+0.06)
KaloBios Announces Retirement of David W. Pritchard, President and Chief Executive Officer
PR Newswire - Thu Jan 08, 3:31PM CST
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that David W. Pritchard, president and chief executive officer, has decided to retire, effective immediately, and has also resigned his position as a member of the company's Board of Directors. The company has named Herb C. Cross, chief financial officer, as interim CEO pending a search for a new chief executive officer.
KBIO: 0.45 (+0.06)
KaloBios Pharmaceuticals' KB001-A Fails Primary Endpoint - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 07, 1:28PM CST
KaloBios Pharmaceuticals, Inc. (KBIO) announced that one of its principal candidates, KB001-A, has failed to meet the primary endpoint in a phase II study.
PGNX: 5.66 (+0.06), ACT: 285.37 (+3.71), KBIO: 0.45 (+0.06), SUPN: 8.80 (+0.22)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Jan 07, 11:45AM CST
KOPN: 3.91 (-0.10), ZFGN: 39.06 (+0.92), CYNI: 3.93 (+0.14), NEON: 2.98 (+0.16), BALT: 1.74 (+0.09), GALT: 3.84 (+0.16), ESNT: 24.18 (+0.16), CHOP: 0.87 (-0.01), LIQT: 1.16 (+0.01), ENPH: 15.15 (+0.37), KBIO: 0.45 (+0.06), NERV: 4.68 (+0.09), REN: 1.14 (unch), FWM: 5.55 (+0.08), COSI: 2.80 (unch), JCP: 8.05 (+0.14), PKT: 8.99 (+0.11), ARNA: 4.55 (+0.02), BGI: 1.41 (-0.05), MERU: 2.74 (-0.01)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Wed Jan 07, 8:20AM CST
FRO: 2.96 (+0.07), GGB: 3.59 (+0.09), KBIO: 0.45 (+0.06), SONC: 31.59 (-0.37), JCP: 8.05 (+0.14), GALT: 3.84 (+0.16), SNE: 27.30 (+0.19), RMTI: 11.17 (+0.15), PKT: 8.99 (+0.11), ARNA: 4.55 (+0.02)
KaloBios Pharma -60% after KB001-A results disappoint
Seeking Alpha - at Seeking Alpha - Tue Jan 06, 3:53PM CST
KBIO: 0.45 (+0.06)
KaloBios Reports Top-Line Data for Phase 2 Study of KB001-A to Treat Pseudomonas Aeruginosa Lung Infections in Cystic Fibrosis Patients
PR Newswire - Tue Jan 06, 3:01PM CST
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced top-line data from the randomized, double-blind, placebo-controlled Phase 2 study of KB001-A, an anti-PcrV monoclonal antibody (mAb) fragment, to treat Pseudomonas aeruginosa (Pa) lung infections in subjects with cystic fibrosis (CF). While the data from this study showed KB001-A was generally safe and well-tolerated, the primary endpoint of increased time to need for antibiotics for worsening respiratory tract signs and symptoms (an indicator of reduction of the risk to develop pulmonary exacerbations) was not met.
KBIO: 0.45 (+0.06)
Myelofibrosis - Pipeline Review, H2 2014
M2 - Wed Dec 10, 4:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/74hp4n/myelofibrosis) has announced the addition of the "Myelofibrosis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Myelofibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myelofibrosis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Myelofibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Myelofibrosis pipeline depth and focus of Indication therapeutics Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Acceleron Pharma - AstraZeneca - Bristol-Myers Squibb - Celgene - CTI BioPharma - Geron Corporation - Gilead Sciences - Incyte - Italfarmaco - KaloBios Pharmaceuticals - MEI Pharma - Nippon Shinyaku - Novartis - Onconova Therapeutics - Pfizer - PharmaEssentia - Promedior - Stemline Therapeutics - Threshold Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/74...lofibrosis
KBIO: 0.45 (+0.06), GILD: 101.90 (+1.10), GERN: 3.03 (unch), ONTX: 2.27 (-0.02), CTIC: 2.23 (-0.02), BMY: 60.04 (+0.56), STML: 14.07 (-0.10), NVS: 102.20 (-0.17), MEIP: 5.00 (-0.04), CELGZ: 3.17 (-0.04), XLRN: 38.02 (+0.07)
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2014
M2 - Tue Dec 02, 6:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/53cpct/chronic) has announced the addition of the "Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Obstructive Pulmonary Disease (COPD) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: 100 companies are cited in this text including: - Ache Laboratorios Farmaceuticos S/A - Adamis Pharmaceuticals Corporation - Advinus Therapeutics Ltd. - AIM Therapeutics Inc. - Axikin Pharmaceuticals, Inc. - Basilea Pharmaceutica AG - Daiichi Sankyo Company, Limited - Errant Gene Therapeutics, LLC - Five Prime Therapeutics, Inc. - GlaxoSmithKline plc - Hydra Biosciences, Inc. - iCeutica, Inc. - Johnson & Johnson - KaloBios Pharmaceuticals, Inc. - Medestea Research & Production S.p.A. - Novartis AG - Ockham Biotech Limited - Pfizer Inc. - PharmaLundensis - Re-Pharm - Seoul Pharma - Takeda Pharmaceutical Company - Zambon Company For more information visit http://www.researchandmarkets.com/research/53cpct/chronic
JNJ: 99.62 (+1.18), KBIO: 0.45 (+0.06), PFE: 34.64 (-0.23), ADMP: 6.50 (-0.01), GSK: 47.94 (+1.99), NVS: 102.20 (-0.17), FPRX: 24.63 (+0.63)
KaloBios names Robert A. Baffi to board
M2 - Mon Dec 01, 7:32AM CST
Monoclonal antibodies company KaloBios Pharmaceuticals (NasdaqGM:KBIO) revealed on Monday the addition of Dr. Robert A. Baffi, Ph.D. to its board of directors.
BMRN: 100.76 (+1.98), KBIO: 0.45 (+0.06)
KaloBios Elects Robert A. Baffi, BioMarin Senior Executive, to Board of Directors
PR Newswire - Mon Dec 01, 7:05AM CST
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced the election of Robert A. Baffi, Ph.D. to the KaloBios Board of Directors. Dr. Baffi is Executive Vice President of Technical Operations at BioMarin Pharmaceutical Inc. (Nasdaq: BMRN).
BMRN: 100.76 (+1.98), KBIO: 0.45 (+0.06)
Akorn (AKRX) Worth Watching: Stock Adds 6.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 7:51AM CST
Akorn, Inc. (AKRX) was a big mover last session, as its shares rose over 6% on the day.
MNK: 115.01 (+2.51), KBIO: 0.45 (+0.06), AKRX: 47.28 (-0.25), MYL: 55.85 (+1.34)
KaloBios Announces Upcoming Scientific and Investor Conference Participation
PR Newswire - Tue Nov 11, 3:05PM CST
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that it will present at the Stifel 2014 Healthcare Conference in November, and that data on the company's KB004 program in hematologic malignancies will be presented in a poster session at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition in early December.
KBIO: 0.45 (+0.06)
KaloBios (KBIO) Looks Good: Stocks Adds 11.1% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 8:25AM CST
KaloBios (KBIO) was a big mover last session, with shares rising over 11% on the day.
MNK: 115.01 (+2.51), IPXL: 39.51 (+0.69), KBIO: 0.45 (+0.06), MYL: 55.85 (+1.34)
KaloBios Pharmaceuticals beats by $0.10
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 4:38PM CST
KBIO: 0.45 (+0.06)
KaloBios Reports Third Quarter Financial Results
PR Newswire - Thu Nov 06, 3:05PM CST
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today reported its financial results for the third quarter of 2014.
KBIO: 0.45 (+0.06)
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2014
M2 - Thu Nov 06, 3:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/7vhcvg/chronic) has announced the addition of the "Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development (Partial List) - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - GlaxoSmithKline plc - Gamida Cell Ltd. - BioLineRx, Ltd. - Piramal Enterprises Limited - Nanotherapeutics, Inc. - Bio-Path Holdings, Inc. - Novartis AG - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Celgene Corporation - Incyte Corporation - Ariad Pharmaceuticals, Inc. - JW Pharmaceutical Corporation - Ilyang Pharmaceutical Co., Ltd - Jiangsu Hengrui Medicine Co., Ltd. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Natco Pharma Limited - Hybrigenics S.A. - SymBio Pharmaceuticals Limited - Nerviano Medical Sciences - Constellation Pharmaceuticals, Inc. - Deciphera Pharmaceuticals, LLC - Stemline Therapeutics, Inc. - Onconova Therapeutics, Inc. - Mirna Therapeutics, Inc. - KaloBios Pharmaceuticals, Inc. - AB Science For more information visit http://www.researchandmarkets.com/research/7vhcvg/chronic
PFE: 34.64 (-0.23), INCY: 75.94 (+0.28), ONTX: 2.27 (-0.02), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), STML: 14.07 (-0.10), SNTA: 2.29 (-0.03), KBIO: 0.45 (+0.06), BPTH: 2.23 (-0.02), CELGZ: 3.17 (-0.04), NVS: 102.20 (-0.17)
KaloBios Announces Upcoming Investor Conference Participation
PR Newswire - Tue Feb 03, 3:01PM CST
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that it will present at the BIO CEO & Investor Conference, and will participate in an analyst-led fireside chat at the Leerink Partners 2015 Global Healthcare Conference next week in New York City, New York.
KBIO: 0.45 (+0.06)
Biotech Weekly: When To Dash For The Trash (And When Not To)
Daniel Ward - at Seeking Alpha - Mon Feb 02, 8:40AM CST
KBIO: 0.45 (+0.06), CYCC: 0.62 (-0.01), TRGT: 2.50 (-0.01), SPHS: 0.44 (-0.01), ABIO: 0.70 (+0.03), APPY: 0.45 (-0.01), OCLS: 0.80 (-0.01)
KaloBios discloses departure of CEO & president David W. Pritchard
M2 - Fri Jan 09, 7:45AM CST
Monoclonal antibodies company KaloBios Pharmaceuticals (NasdaqGM:KBIO) announced on Thursday the retirement of David W. Pritchard as its president and chief executive officer with immediate effect.
KBIO: 0.45 (+0.06)
KaloBios CEO Pritchard resigns; shares -7.4% AH
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 5:45PM CST
KBIO: 0.45 (+0.06)
KaloBios Announces Retirement of David W. Pritchard, President and Chief Executive Officer
PR Newswire - Thu Jan 08, 3:31PM CST
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that David W. Pritchard, president and chief executive officer, has decided to retire, effective immediately, and has also resigned his position as a member of the company's Board of Directors. The company has named Herb C. Cross, chief financial officer, as interim CEO pending a search for a new chief executive officer.
KBIO: 0.45 (+0.06)
KaloBios Pharmaceuticals' KB001-A Fails Primary Endpoint - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 07, 1:28PM CST
KaloBios Pharmaceuticals, Inc. (KBIO) announced that one of its principal candidates, KB001-A, has failed to meet the primary endpoint in a phase II study.
PGNX: 5.66 (+0.06), ACT: 285.37 (+3.71), KBIO: 0.45 (+0.06), SUPN: 8.80 (+0.22)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Jan 07, 11:45AM CST
KOPN: 3.91 (-0.10), ZFGN: 39.06 (+0.92), CYNI: 3.93 (+0.14), NEON: 2.98 (+0.16), BALT: 1.74 (+0.09), GALT: 3.84 (+0.16), ESNT: 24.18 (+0.16), CHOP: 0.87 (-0.01), LIQT: 1.16 (+0.01), ENPH: 15.15 (+0.37), KBIO: 0.45 (+0.06), NERV: 4.68 (+0.09), REN: 1.14 (unch), FWM: 5.55 (+0.08), COSI: 2.80 (unch), JCP: 8.05 (+0.14), PKT: 8.99 (+0.11), ARNA: 4.55 (+0.02), BGI: 1.41 (-0.05), MERU: 2.74 (-0.01)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Wed Jan 07, 8:20AM CST
FRO: 2.96 (+0.07), GGB: 3.59 (+0.09), KBIO: 0.45 (+0.06), SONC: 31.59 (-0.37), JCP: 8.05 (+0.14), GALT: 3.84 (+0.16), SNE: 27.30 (+0.19), RMTI: 11.17 (+0.15), PKT: 8.99 (+0.11), ARNA: 4.55 (+0.02)
KaloBios Pharma -60% after KB001-A results disappoint
Seeking Alpha - at Seeking Alpha - Tue Jan 06, 3:53PM CST
KBIO: 0.45 (+0.06)
KaloBios Reports Top-Line Data for Phase 2 Study of KB001-A to Treat Pseudomonas Aeruginosa Lung Infections in Cystic Fibrosis Patients
PR Newswire - Tue Jan 06, 3:01PM CST
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced top-line data from the randomized, double-blind, placebo-controlled Phase 2 study of KB001-A, an anti-PcrV monoclonal antibody (mAb) fragment, to treat Pseudomonas aeruginosa (Pa) lung infections in subjects with cystic fibrosis (CF). While the data from this study showed KB001-A was generally safe and well-tolerated, the primary endpoint of increased time to need for antibiotics for worsening respiratory tract signs and symptoms (an indicator of reduction of the risk to develop pulmonary exacerbations) was not met.
KBIO: 0.45 (+0.06)
Myelofibrosis - Pipeline Review, H2 2014
M2 - Wed Dec 10, 4:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/74hp4n/myelofibrosis) has announced the addition of the "Myelofibrosis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Myelofibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myelofibrosis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Myelofibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Myelofibrosis pipeline depth and focus of Indication therapeutics Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Acceleron Pharma - AstraZeneca - Bristol-Myers Squibb - Celgene - CTI BioPharma - Geron Corporation - Gilead Sciences - Incyte - Italfarmaco - KaloBios Pharmaceuticals - MEI Pharma - Nippon Shinyaku - Novartis - Onconova Therapeutics - Pfizer - PharmaEssentia - Promedior - Stemline Therapeutics - Threshold Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/74...lofibrosis
KBIO: 0.45 (+0.06), GILD: 101.90 (+1.10), GERN: 3.03 (unch), ONTX: 2.27 (-0.02), CTIC: 2.23 (-0.02), BMY: 60.04 (+0.56), STML: 14.07 (-0.10), NVS: 102.20 (-0.17), MEIP: 5.00 (-0.04), CELGZ: 3.17 (-0.04), XLRN: 38.02 (+0.07)
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2014
M2 - Tue Dec 02, 6:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/53cpct/chronic) has announced the addition of the "Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Obstructive Pulmonary Disease (COPD) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: 100 companies are cited in this text including: - Ache Laboratorios Farmaceuticos S/A - Adamis Pharmaceuticals Corporation - Advinus Therapeutics Ltd. - AIM Therapeutics Inc. - Axikin Pharmaceuticals, Inc. - Basilea Pharmaceutica AG - Daiichi Sankyo Company, Limited - Errant Gene Therapeutics, LLC - Five Prime Therapeutics, Inc. - GlaxoSmithKline plc - Hydra Biosciences, Inc. - iCeutica, Inc. - Johnson & Johnson - KaloBios Pharmaceuticals, Inc. - Medestea Research & Production S.p.A. - Novartis AG - Ockham Biotech Limited - Pfizer Inc. - PharmaLundensis - Re-Pharm - Seoul Pharma - Takeda Pharmaceutical Company - Zambon Company For more information visit http://www.researchandmarkets.com/research/53cpct/chronic
JNJ: 99.62 (+1.18), KBIO: 0.45 (+0.06), PFE: 34.64 (-0.23), ADMP: 6.50 (-0.01), GSK: 47.94 (+1.99), NVS: 102.20 (-0.17), FPRX: 24.63 (+0.63)
KaloBios names Robert A. Baffi to board
M2 - Mon Dec 01, 7:32AM CST
Monoclonal antibodies company KaloBios Pharmaceuticals (NasdaqGM:KBIO) revealed on Monday the addition of Dr. Robert A. Baffi, Ph.D. to its board of directors.
BMRN: 100.76 (+1.98), KBIO: 0.45 (+0.06)
KaloBios Elects Robert A. Baffi, BioMarin Senior Executive, to Board of Directors
PR Newswire - Mon Dec 01, 7:05AM CST
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced the election of Robert A. Baffi, Ph.D. to the KaloBios Board of Directors. Dr. Baffi is Executive Vice President of Technical Operations at BioMarin Pharmaceutical Inc. (Nasdaq: BMRN).
BMRN: 100.76 (+1.98), KBIO: 0.45 (+0.06)
Akorn (AKRX) Worth Watching: Stock Adds 6.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 7:51AM CST
Akorn, Inc. (AKRX) was a big mover last session, as its shares rose over 6% on the day.
MNK: 115.01 (+2.51), KBIO: 0.45 (+0.06), AKRX: 47.28 (-0.25), MYL: 55.85 (+1.34)
KaloBios Announces Upcoming Scientific and Investor Conference Participation
PR Newswire - Tue Nov 11, 3:05PM CST
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that it will present at the Stifel 2014 Healthcare Conference in November, and that data on the company's KB004 program in hematologic malignancies will be presented in a poster session at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition in early December.
KBIO: 0.45 (+0.06)
KaloBios (KBIO) Looks Good: Stocks Adds 11.1% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 8:25AM CST
KaloBios (KBIO) was a big mover last session, with shares rising over 11% on the day.
MNK: 115.01 (+2.51), IPXL: 39.51 (+0.69), KBIO: 0.45 (+0.06), MYL: 55.85 (+1.34)
KaloBios Pharmaceuticals beats by $0.10
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 4:38PM CST
KBIO: 0.45 (+0.06)
KaloBios Reports Third Quarter Financial Results
PR Newswire - Thu Nov 06, 3:05PM CST
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today reported its financial results for the third quarter of 2014.
KBIO: 0.45 (+0.06)
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2014
M2 - Thu Nov 06, 3:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/7vhcvg/chronic) has announced the addition of the "Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development (Partial List) - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - GlaxoSmithKline plc - Gamida Cell Ltd. - BioLineRx, Ltd. - Piramal Enterprises Limited - Nanotherapeutics, Inc. - Bio-Path Holdings, Inc. - Novartis AG - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Celgene Corporation - Incyte Corporation - Ariad Pharmaceuticals, Inc. - JW Pharmaceutical Corporation - Ilyang Pharmaceutical Co., Ltd - Jiangsu Hengrui Medicine Co., Ltd. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Natco Pharma Limited - Hybrigenics S.A. - SymBio Pharmaceuticals Limited - Nerviano Medical Sciences - Constellation Pharmaceuticals, Inc. - Deciphera Pharmaceuticals, LLC - Stemline Therapeutics, Inc. - Onconova Therapeutics, Inc. - Mirna Therapeutics, Inc. - KaloBios Pharmaceuticals, Inc. - AB Science For more information visit http://www.researchandmarkets.com/research/7vhcvg/chronic
PFE: 34.64 (-0.23), INCY: 75.94 (+0.28), ONTX: 2.27 (-0.02), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), STML: 14.07 (-0.10), SNTA: 2.29 (-0.03), KBIO: 0.45 (+0.06), BPTH: 2.23 (-0.02), CELGZ: 3.17 (-0.04), NVS: 102.20 (-0.17)
